House Appropriators Stoke Flames For FDA Regulation On CBD In Supplements
Executive Summary
House Appropriations subcommittee with FDA oversight makes clear in questions for Commissioner Gottlieb they support allowing use of constituent ingredients from hemp and cannabis plants in food and dietary supplement products. Members also press for approving US firms' applications for pharmaceuticals with cannabis-derived active ingredients. Gottlieb announces working group will guide FDA decisions on potential CBD-use rulemaking.
You may also be interested in...
Will DEA Saying Synthetic THCs Are Controlled Substances Help Deliver Lawful Hemp Answer?
DEA’s explanation delta-8 THC acetate isn’t hemp, along with FDA’s hemp and cannabis policies chief saying it and other cannabis derivatives aren’t hemp, should simplify decision on lawful use of hemp in non-drug products subject to FDA’s regulatory oversight.
Is US Hemp Policy Heading For Farm Bill, Act III?
It could take next farm bill, on lawmakers’ 2023 to-do list, to extinguish inferno of disagreement between FDA and regulated industries over lawful use of hemp-based ingredients in supplements as well as food and non-drug topicals. Before 2018 bill de-scheduled hemp, 2014 bill expanded access to hemp for research.
Legislating US Regulatory Pathway For Cannabinoids ‘Not End of The World’ – Gottlieb
Former FDA commissioner says legislative carve-out for a regulatory pathway for cannabinoids is a better option than a rulemaking, which could take five years and “may not even work.” Cannabinoids market is “well far ahead of where the regulation is,” he says.